ATE498398T1 - Cycloalkyl-heterozyklen zur behandlung des hepatitis-c-virus - Google Patents

Cycloalkyl-heterozyklen zur behandlung des hepatitis-c-virus

Info

Publication number
ATE498398T1
ATE498398T1 AT04782095T AT04782095T ATE498398T1 AT E498398 T1 ATE498398 T1 AT E498398T1 AT 04782095 T AT04782095 T AT 04782095T AT 04782095 T AT04782095 T AT 04782095T AT E498398 T1 ATE498398 T1 AT E498398T1
Authority
AT
Austria
Prior art keywords
hepatitis
virus
treatment
heterocycles
cycloalkyl
Prior art date
Application number
AT04782095T
Other languages
German (de)
English (en)
Inventor
Peter Glunz
Brent Douty
Scott Martin
Jeffrey Romine
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE498398T1 publication Critical patent/ATE498398T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT04782095T 2003-09-11 2004-08-24 Cycloalkyl-heterozyklen zur behandlung des hepatitis-c-virus ATE498398T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50206703P 2003-09-11 2003-09-11
PCT/US2004/027533 WO2005034850A2 (en) 2003-09-11 2004-08-24 Cycloalkyl heterocycles for treating hepatitis c virus

Publications (1)

Publication Number Publication Date
ATE498398T1 true ATE498398T1 (de) 2011-03-15

Family

ID=34434839

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04782095T ATE498398T1 (de) 2003-09-11 2004-08-24 Cycloalkyl-heterozyklen zur behandlung des hepatitis-c-virus

Country Status (7)

Country Link
US (1) US7112601B2 (enExample)
EP (1) EP1663105B1 (enExample)
JP (1) JP4897484B2 (enExample)
AT (1) ATE498398T1 (enExample)
DE (1) DE602004031435D1 (enExample)
ES (1) ES2358904T3 (enExample)
WO (1) WO2005034850A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT502258B1 (de) * 2005-07-22 2007-09-15 Univ Wien Cox-i-inhibitorverbindungen
WO2007019397A2 (en) * 2005-08-05 2007-02-15 Genelabs Technologies, Inc. 6-membered aryl and heteroaryl derivatives for the treatment of hepatitis c virus
BRPI0716060A2 (pt) * 2006-08-17 2013-09-17 Boehringer Ingelheim Int inibidores de polimerase viral.
AU2008219622A1 (en) 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Methods for the treatment of liver diseases using specified matrix metalloproteinase (MMP) inhibitors
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
EP2494991A1 (en) 2007-05-04 2012-09-05 Vertex Pharmaceuticals Incorporated Combination therapy for the treatment of HCV infection
WO2009028418A1 (ja) 2007-08-24 2009-03-05 Sapporo Medical University シクロスポリンａ結合タンパク質
EA201000948A1 (ru) 2007-12-19 2011-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Ингибиторы вирусной полимеразы
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
MX2011007195A (es) 2009-01-07 2013-07-12 Scynexis Inc Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
MX2013007677A (es) 2010-12-30 2013-07-30 Abbvie Inc Inhibidores macrociclicos de serina proteasa de hepatitis.
EP2658858A4 (en) 2010-12-30 2014-06-25 Enanta Pharm Inc MACROCYCLIC INHIBITORS OF HEPATITIS C SERINE PROTEASE PHENANTHRIDINE
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
US11724997B2 (en) 2018-03-01 2023-08-15 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with APJ receptor activity

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ322674A (en) * 1995-10-17 1999-08-30 Searle & Co Method of detecting cyclooxygenase-2
AU756627B2 (en) 1998-07-27 2003-01-16 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Diketoacid-derivatives as inhibitors of polymerases
IL141456A0 (en) 1998-08-21 2002-03-10 Viropharma Inc Rhodanine derivatives and pharmaceutical compositions containing the same
CN1324250A (zh) 1998-09-04 2001-11-28 维洛药品公司 治疗或预防病毒感染及其所致疾病的方法
WO2000018231A1 (en) 1998-09-25 2000-04-06 Viropharma Incorporated Methods for treating or preventing viral infections and associated diseases
WO2000024725A1 (en) * 1998-10-26 2000-05-04 Vertex Pharmaceuticals Incorporated Pentacyclic compounds useful as inhibitors of hepatitis c virus ns3 helicase
AU1262001A (en) 1999-11-04 2001-05-14 Biochem Pharma Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
SK13752001A3 (sk) 1999-12-27 2002-07-02 Japan Tobacco, Inc. Zlúčeniny s fúzovanými kruhmi a ich použitie ako liečiv
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
EP1256628A3 (en) 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
PL395097A1 (pl) 2001-06-11 2011-10-10 Vertex Pharmaceuticals (Canada) Incorporated Sposób wytwarzania związku o wzorze A stanowiącego pochodną tiofenu
AR035543A1 (es) * 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
CA2448737C (en) 2001-07-20 2010-06-01 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
WO2003026587A2 (en) * 2001-09-26 2003-04-03 Bristol-Myers Squibb Company Compounds useful for treating hepatitus c virus

Also Published As

Publication number Publication date
EP1663105A4 (en) 2009-04-15
JP4897484B2 (ja) 2012-03-14
US20050075376A1 (en) 2005-04-07
DE602004031435D1 (de) 2011-03-31
EP1663105B1 (en) 2011-02-16
JP2007505114A (ja) 2007-03-08
WO2005034850A3 (en) 2006-03-16
WO2005034850A2 (en) 2005-04-21
EP1663105A2 (en) 2006-06-07
US7112601B2 (en) 2006-09-26
ES2358904T3 (es) 2011-05-16

Similar Documents

Publication Publication Date Title
EA200700338A1 (ru) Ингибиторы рнк-зависимой рнк-полимеразы вируса гепатита с и композиции и способы лечения с их использованием
DE602008004317D1 (de) Verbindungen zur behandlung von hepatitis c
ATE522532T1 (de) Verbindungen zur behandlung von hepatitis c
PL1987038T3 (pl) Inhibitory HCV NS5B
ATE469155T1 (de) Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b- hemmer
EA200802346A1 (ru) Циклопропилконденсированные индолобензазепиновые ингибиторы белка ns5b вируса гепатита с
UY28323A1 (es) Compuestos inhibidores de la hepatitis c
ATE551343T1 (de) Tetracyclische verbindungen zur behandlung von hepatitis c
TW200518746A (en) Novel inhibitors of hepatitis C virus NS3/NS4A serine protease
WO2004002940A8 (en) Inhibitors of hcv ns5b polymerase
EA200900298A1 (ru) Ингибиторы вируса гепатита с
TW200745120A (en) Indolobenzazepine HCV NS5B inhibitors
EA200800371A1 (ru) Ингибиторы ns3 протеазы вгс
EA201001273A1 (ru) Ингибиторы вируса гепатита с
JO2318B1 (en) Nucleoside derivatives used as DNA-based viral RNA inhibitors
ATE498398T1 (de) Cycloalkyl-heterozyklen zur behandlung des hepatitis-c-virus
ATE505473T1 (de) Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c
MX337050B (es) Compuestos 4'-azido-nucleósidos como anti-vhc.
DK2209789T3 (da) Cyclopropyl-kondenserede indolobenzazepin HCV NS5B-hæmmere
ATE432922T1 (de) Substituierte 5-carboxyamidpyrazoles und ä1,2, 4ütriazole als viruzide
MX2010001416A (es) Compuesto para el tratamiento de la hepatitis c.
UA90909C2 (en) Hcv ns3 protease inhibitors
ATE491706T1 (de) Heterocyclische antivirale verbindungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties